Record quarter masks FY27 caution; Europe breakout offsets guidance gap

EBITDA ₹213 Cr at 25.3% margin, up 112.8% YoY from ₹100.1 Cr

Total Europe revenue ₹356 Cr (74.7% YoY); ₹356 - ₹44 = ₹312 Cr organic; implies ₹312 / baseline ≈ 53% YoY growth

Current 59.1% inflated by favorable mix, depleting low-cost inventory, and FX tailwind; management acknowledges temporary drivers

North America ₹377 Cr at 15.1% YoY; 45% of ₹840.8 total confirmed

Currently ₹841 Cr annualized implies ₹3,364 Cr run-rate; reaching ₹4,000 in FY28 requires ~19% CAGR from FY27

Prior guidance said 'M&A expected in 2027'; already closed QliniQ (Netherlands) and ABCnow (Germany) in 2026. Europe target ₹180 Cr FY27 vs implicit lower base in prior guidance.

Prior 15-20% revenue growth and 20-21% EBITDA margin reaffirmed. Management cited 'geopolitical volatility' as reason to hold despite 35.6% Q1 growth. Implies caution on sustainability.

55-56% flagged as sustainable level vs current 59.1%, acknowledging inventory depletion and FX tailwind are temporary. Implies 300-400 bps margin contraction risk if current drivers reverse.

QliniQ effective April 1, ₹44 Cr Q1 revenue. Full year expect ₹150-175 Cr from QliniQ. Overall Europe ₹180 Cr target. Organic ex-QliniQ grew 53.1% YoY.

Fluid situation. Sitting on good inventory but war/freight/raw material costs offset gains. War ends → normalizes fast. Sustainable is 55-56%. Some inventory remains.

No, will stick with plan due to geopolitical volatility and uncertainties. Stand by historical projection.

Will be able to sustain it.

Germany early Q3, better revenue expected. Ireland takes time (licenses needed), hopeful next fiscal year, not this year.

Expanding OTC portfolio and brands. Lot of work, will invest resources, confident in direction but vague on specifics.

No definite timeline. Can come any moment. One plant audited <12 months back. Depends on filings.

Yes. From revenue standpoint, Q2 better than Q1, Q3 probably strongest. Will hit expected EBITDA margins.

Two acquisitions done (Netherlands, Germany). Good launching pad. Grew very well on past acquisitions. Will need more acquisitions. Have corpus for inorganic strategies. M&A unpredictable.

Possibility always exists but don't put weightage on statements—change within days. Two years long; things may change with elections. Will watch and see.

No, unrealistic. 55-56% range more comfortable given geopolitical scenarios, war, crude, transportation.

65-70%, 70% higher side. From India.

Not pursuing actively. Developed some IPs on DMFs, exploring CRAMS module, but not active given macro.

Unlike last year, all markets and geographies will do fairly well. Each subsidiary will contribute.

No, don't take that risk. Main aim is inorganic strategies to grow revenue. Acquisitions return faster than instruments. Averse to risk beyond control.

End of year 21-22% EBITDA is achievable.

UK growth all organic, no inorganic in UK. QliniQ is revenue (not cash received). UK organic grew >50% YoY.

Europe cluster of many countries, present in two. Plan to expand, mostly via acquisitions. Within 5 years, Europe can do ₹1,000 Cr.

Progressing well. Projected ₹80 Cr revenue. Currently at ₹50+ Cr, so 60-65% utilization.

Looking at couple targets. Too early. Have 1-2 years to work on objective. May need another plant in India. Nothing concrete. Need to get right price.

UK equally split: 55% Rx, 45% OTC. Europe tilting Rx: 80-85% Rx, 15% OTC (prescription market).

No longer talking $200 Mn, working towards $300 Mn next, then $400 Mn if 5-year horizon. Immediate objective $300 Mn.

Focusing on product development, different delivery forms (more expensive). Doubling portfolio in every country in 2-3 years. Better resources as company grows larger.

Don't see much change. See struggles from war/geopolitical scenarios, fuel prices, consumer affordability. Don't see competition changing. Some big players struggling (good news).

Anything possible. Smaller markets explore strategies; India acquisition means bigger valuation. ₹200-400 Cr could go to single deal. Money fuels growth. Year for inorganic strategy.

In last call, spoke of doubling revenue (3-5 years). How many companies talk of doubling? From ₹3,000 Cr, doubling within 5 years is visibility. Still working towards it.

Reaffirmed despite 35.6% Q1 growth. Management cited geopolitical volatility and macro uncertainty as reasons for conservatism.

Current 25.3% driven by favorable mix, inventory, FX (all temporary). 55-56% gross margin sustainable. Some pressure expected QoQ.

Needed for 3-5 year doubling target. Nothing concrete; targeting 'right price'. Goa unit 2 at 60-65% utilization.

Current 59.1% margin driven by low-cost inventory depletion (ending), favorable FX, and product mix. Management guides 55-56% sustainable, implying 300-400 bps compression risk if drivers reverse mid-year.

Q1 grew 35.6% YoY but FY27 guidance is only 15-20% growth, implying sharp deceleration in H2. If current momentum sustains (as early indicators suggest), guidance will be massively beaten and credibility questioned.

QliniQ and ABCnow acquisitions just completed. Integration execution risk (synergies, cultural, operational). Ireland entity needs licensing (wholesale, distribution, product); revenue not expected until FY28.

Three USFDA-compliant plants globally. Inspection timing unpredictable; one facility audited <12 months back. Large US revenue exposure (45%) creates dependency on regulatory clearance.

War-related freight inflation, raw material cost pressure, consumer affordability concerns (fuel prices), and geopolitical uncertainty cited as reasons for cautious FY27 guidance. Non-Western markets (Rest of World) explicitly struggling.